Erdheim-Chester病一例

doi:10.3760/cma.j.cn101202-20210224-00050

摘要
图/表
参考文献
相关文章 (4)

[1]	Poellinger A, Hrycyk J. Erdheim-Chester disease[J]. Mayo Clin Proc, 2019, 94(5): 924-925. DOI:10.1016/j.mayocp.2019.01.026.
[2]	Papo M, Emile JF, Maciel TT, et al. Erdheim-Chester disease: a concise review[J]. Curr Rheumatol Rep, 2019, 21(12): 66. DOI:10.1007/s11926-019-0865-2.
[3]	Vaglio A, Diamond EL. Erdheim-Chester disease: the “targeted” revolution[J]. Blood, 2017, 130(11): 1282-1284. DOI:10.1182/blood-2017-07-795054.
[4]	Goyal G, Heaney ML, Collin M, et al. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era[J]. Blood, 2020, 135(22): 1929-1945. DOI:10.1182/blood.2019003507.
[5]	Haroche J, Cohen-Aubart F, Amoura Z. Erdheim-Chester disease[J]. Blood, 2020, 135(16): 1311-1318. DOI:10.1182/blood.2019002766.
[6]	Estrada-Veras JI, O'Brien KJ, et al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study[J]. Blood Adv, 2017, 1(6): 357-366. DOI:10.1182/bloodadvances.2016001784.
[7]	Pegoraro F, Papo M, Maniscalco V, et al. Erdheim-Chester disease: a rapidly evolving disease model[J]. Leukemia, 2020, 34(11): 2840-2857. DOI:10.1038/s41375-020-0944-4.
[8]	Haroche J, Amoura Z, Dion E, et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review[J]. Medicine (Baltimore), 2004, 83(6): 371-392. DOI:10.1097/01.md.0000145368.17934.91.
[9]	Bhatia A, Hatzoglou V, Ulaner G, et al. Neurologic and oncologic features of Erdheim-Chester disease: a 30-patient series[J]. Neuro Oncol, 2020, 22(7): 979-992. DOI:10.1093/neuonc/noaa008.
[10]	Yelfimov DA, Lightner DJ, Tollefson MK. Urologic manifestations of Erdheim-Chester disease[J]. Urology, 2014, 84(1): 218-221. DOI:10.1016/j.urology.2013.10.023.
[11]	Scolaro JC, Peiris AN. The hairy kidney of Erdheim-Chester disease[J]. Mayo Clin Proc, 2018, 93(5): 671. DOI:10.1016/j.mayocp.2018.03.003.
[12]	Brun AL, Touitou-Gottenberg D, Haroche J, et al. Erdheim-Chester disease: CT findings of thoracic involvement[J]. Eur Radiol, 2010, 20(11): 2579-2587. DOI:10.1007/s00330-010-1830-7.
[13]	Courtillot C, Laugier Robiolle S, Cohen Aubart F, et al. Endocrine manifestations in a monocentric cohort of 64 patients with Erdheim-Chester disease[J]. J Clin Endocrinol Metab, 2016, 101(1): 305-313. DOI:10.1210/jc.2015-3357.
[14]	Nikpanah M, Kim L, Mirmomen SM, et al. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF(V600E) mutation[J]. Eur Radiol, 2018, 28(9): 3751-3759. DOI:10.1007/s00330-018-5326-1.
[15]	Mirmomen SM, Sirajuddin A, Nikpanah M, et al. Thoracic involvement in Erdheim-Chester disease: computed tomography imaging findings and their association with the BRAF(V600E) mutation[J]. Eur Radiol, 2018, 28(11): 4635-4642. DOI:10.1007/s00330-018-5421-3.
[16]	Young JR, Johnson GB, Murphy RC, et al. 18F-FDG PET/CT in Erdheim-Chester disease: imaging findings and potential BRAF mutation biomarker[J]. J Nucl Med, 2018, 59(5): 774-779. DOI:10.2967/jnumed.117.200741.
[17]	Goyal G, Shah MV, Call TG, et al. Clinical and radiologic responses to cladribine for the treatment of Erdheim-Chester disease[J]. JAMA Oncol, 2017, 3(9): 1253-1256. DOI:10.1001/jamaoncol.2017.0041.
[18]	Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis[J]. Blood, 2020, 135(16): 1319-1331. DOI:10.1182/blood.2019000934.